SeattleGenetics®

TRANSFORMATIVE THERAPIES | TARGETING CANCER

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives.

ADCETRIS® (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies and targeted therapies to build a portfolio of programs for hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland.

Our antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.



Various combinations of these novel modalities are likely to be the future of treatment in oncology

QUICK FACTS

YEARS: Celebrating 20th anniversary in 2018

SIZE: Largest biotechnology company in the Pacific Northwest

EMPLOYEES: 1,225+ employees worldwide

PASSION: Helping people with cancer

LEADERS: In antibody-drug conjugate (ADC) technology

COMMERCIAL PRODUCT: ADCETRIS® (brentuximab vedotin) for multiple CD30-expressing lymphomas

RESEARCH & DEVELOPMENT: >750 scientists dedicated to developing our next innovations, and medical and clinical researchers focused on improving patient outcomes with targeted treatment options, including three unique programs in ongoing or planned pivotal clinical trials

COLLABORATIONS: Multiple ADC technology licensing agreements; co-development collaborations with other oncology industry leaders

LOCATIONS: Greater Seattle, Washington, United States, and Zug, Switzerland

For more information on our company and our robust pipeline, we encourage you to visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

SeattleGenetics®

ADVANCING LATE-STAGE CLINICAL TRIALS AND AN EXPANDING DEVELOPMENT PORTFOLIO

BRENTUXIMAB VEDOTIN

We have a broad ADCETRIS® (brentuximab vedotin) clinical development program evaluating its potential to become the foundation of therapy for CD30-expressing lymphomas.

Non-Hodgkin Lymphoma (NHL)

- ECHELON-2: Frontline CD30-expressing peripheral T-cell lymphoma (PTCL, also known as MTCL)
- CheckMate 436: Relapsed NHL (+ nivolumab)

Hodgkin Lymphoma (HL)

- CheckMate 812: Relapsed HL (+ nivolumab)
- Frontline HL in patients 60+ (+ nivolumab)
- Second-line HL (+ nivolumab)
- CheckMate 744: Relapsed cHL (+ nivolumab) (pediatric)

LATE-STAGE PROGRAMS

We believe our multiple promising late-stage programs have the potential to help us achieve our goal of bringing additional new treatment options to patients in need.

Solid Tumors

- Enfortumab vedotin[1]: EV-301 – Urothelial cancer post-checkpoint inhibitor
- Enfortumab vedotin[1]: EV-201 – Urothelial cancer post-checkpoint inhibitor — PIVOTAL
- Enfortumab vedotin[1]: EV-103 – First-line urothelial cancer (+ checkpoint inhibitor and other agents)
- Tisotumab vedotin[2]: innovaTV 204 – Cervical cancer — PIVOTAL
- Tisotumab vedotin[2]: innovaTV 207 – Other solid tumors

Breast Cancer

- Tucatinib: HER2CLIMB – HER2-positive breast cancer — PIVOTAL
- Ladiratuzumab vedotin: I-SPY 2 – HER2-negative breast cancer
- Ladiratuzumab vedotin: Triple negative breast cancer (TNBC) (+ pembrolizumab)
- Ladiratuzumab vedotin: MORPHEUS – TNBC (+ atezolizumab)
- Ladiratuzumab vedotin: Breast cancer

EARLY-STAGE PROGRAMS

- SEA-CD40: Advanced solid tumors and lymphoma (+/– checkpoint inhibitor)
- SGN-2FF: Advanced solid tumors
- ACTR-BCMA[3]: Multiple myeloma
- SGN-CD48A: Multiple myeloma

[1] Program being developed in collaboration with Astellas
[2] Program being developed in collaboration with Genmab
[3] Program being developed in collaboration with Unum

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.